Prognostic Value of Serum Soluble PD-L1 in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab
Anticancer Research · 2023-02 · 43 (2) · 841-847
DOI: 10.21873/anticanres.16226 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, online erschienen am 25.01.2023. Verfasst von Naoto Wakita und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan; complus_duefl@yahoo.co.jp. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan; complus_duefl@yahoo.co.jp.
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
- Department of Urology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
Zitieren
APA
Wakita, N., Hinata, N., Bando, Y., Hara, T., Terakawa, T., Furukawa, J., Nakano, Y., & Fujisawa, M. (2023). Prognostic Value of Serum Soluble PD-L1 in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab. Anticancer Research, 43(2), 841-847. https://doi.org/10.21873/anticanres.16226
Vancouver
Wakita N, Hinata N, Bando Y, Hara T, Terakawa T, Furukawa J, et al. Prognostic Value of Serum Soluble PD-L1 in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab. Anticancer Research. 2023;43(2):841-847. doi:10.21873/anticanres.16226
BibTeX
@article{Wakita2023,
author = {Wakita, Naoto and Hinata, Nobuyuki and Bando, Yukari and Hara, Takuto and Terakawa, Tomoaki and Furukawa, Junya and Nakano, Yuzo and Fujisawa, Masato},
title = {Prognostic Value of Serum Soluble PD-L1 in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab},
journal = {Anticancer Research},
year = {2023},
volume = {43},
number = {2},
pages = {841--847},
doi = {10.21873/anticanres.16226}
}
EUVIMED